Sterling Bio Machines provides scalable, automated bioreactor technology engineered specifically for complex allogeneic cell therapy manufacturing workflows. Their modular system supports identical controls from benchtop research through GMP production, ensuring data integrity across development phases. The platform utilizes smart sensors and aggregate control to deliver high yields, reduced shear stress, and hands-free operation for pluripotent cell expansion.
Funding
Funding not disclosed
Founders
Product
Problem
Traditional bioreactors often suffer from low yield and scalability issues, leading to high production costs and hindering innovation in biomanufacturing. These limitations restrict the types of cell cultures that can be used and prolong the time required to reach commercial production.
Solution
Sterling Bio Machines is developing a bioreactor system that integrates advanced hardware and software to enhance resource efficiency and reduce production costs in biomanufacturing. The system aims to improve scalability and enable the use of new cell cultures that are incompatible with existing bioreactors. By optimizing the biomanufacturing process, Sterling Bio Machines intends to accelerate the path to commercial production for a wider range of biomanufactured products. The system combines hardware and software to reduce the costs of production, improve resource efficiency, and shorten the time to reach commercial production for biomanufacturing products.
Target Audience
The primary target audience includes companies in the biomanufacturing sector producing medicines, materials, food, fuel, and chemicals.
Features
- Advanced hardware design optimized for resource efficiency.
- Integrated software platform for process control and monitoring.
- Enhanced scalability compared to traditional bioreactor systems.
- Compatibility with a wider range of cell cultures.
- Streamlined workflow to accelerate commercial production timelines.